SandyGeorgia (talk | contribs) →Evolutionary considerations: remove to talk. again |
→Primary: moved and summarized |
||
Line 37: | Line 37: | ||
[[Image:Osteoarthritis left knee.jpg|thumb|Primary osteoarthritis of the left knee. Note the [[osteophytes]], narrowing of the joint space (arrow), and increased subchondral bone density (arrow).]] |
[[Image:Osteoarthritis left knee.jpg|thumb|Primary osteoarthritis of the left knee. Note the [[osteophytes]], narrowing of the joint space (arrow), and increased subchondral bone density (arrow).]] |
||
A number of studies have shown that there is a greater prevalence of the disease among [[sibling]]s and especially [[Semiidentical twins|identical twins]], indicating a hereditary basis.<ref name="pmid18687274">{{cite journal | author = Valdes AM, Spector TD | title = The contribution of genes to osteoarthritis | journal = Rheum. Dis. Clin. North Am. | volume = 34 | issue = 3 | pages = 581–603 | year = 2008 | month = August | pmid = 18687274 | doi = 10.1016/j.rdc.2008.04.008 }}</ref> |
A number of studies have shown that there is a greater prevalence of the disease among [[sibling]]s and especially [[Semiidentical twins|identical twins]], indicating a hereditary basis.<ref name="pmid18687274">{{cite journal | author = Valdes AM, Spector TD | title = The contribution of genes to osteoarthritis | journal = Rheum. Dis. Clin. North Am. | volume = 34 | issue = 3 | pages = 581–603 | year = 2008 | month = August | pmid = 18687274 | doi = 10.1016/j.rdc.2008.04.008 }}</ref> Although a single factor is not generally sufficient to cause the disease, about half of the variation in susceptibility has been assigned to genetic factors.<ref name="pmid14698640">{{cite journal | author = Spector TD, MacGregor AJ | title = Risk factors for osteoarthritis: genetics | journal = Osteoarthr. Cartil. | volume = 12 Suppl A | issue = | pages = S39–44 | year = 2004 | pmid = 14698640 | doi = 10.1016/j.joca.2003.09.005 }}</ref> |
||
As early human ancestors evolved into bipeds, changes occurred in the pelvis, hip joint and spine which increased the risk of osteoarthritis.<ref>{{cite journal|last=Hogervorst|first=T|coauthors=Bouma, HW; de Vos, J|title=Evolution of the hip and pelvis.|journal=Acta orthopaedica. Supplementum|date=2009 Aug|volume=80|issue=336|pages=1-39|pmid=19919389}}</ref> Additionally genetic variations that increase the risk were likely not selected against because usually problems only occur after reproductive success.<ref>{{cite journal|last=van der Kraan|first=PM|coauthors=van den Berg, WB|title=Osteoarthritis in the context of ageing and evolution. Loss of chondrocyte differentiation block during ageing.|journal=Ageing research reviews|date=2008 Apr|volume=7|issue=2|pages=106-13|pmid=18054526}}</ref> |
|||
The development of OA is correlated with a history of previous joint injury and with obesity, especially with respect to knees.<ref name="pmid11360143">{{cite journal | author = Coggon D, Reading I, Croft P, McLaren M, Barrett D, Cooper C | title = Knee osteoarthritis and obesity | journal = Int. J. Obes. Relat. Metab. Disord. | volume = 25 | issue = 5 | pages = 622–7 | year = 2001 | month = May | pmid = 11360143 | doi = 10.1038/sj.ijo.0801585 }}</ref> Since the correlation with obesity has been observed not only for knees but also for non-weight bearing joints and the loss of body fat is more closely related to symptom relief than the loss of body weight, it has been suggested that there may be a metabolic link to body fat as opposed to just mechanical loading.<ref name="pmid17038451">{{cite journal | author = Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F | title = Obesity and osteoarthritis: more complex than predicted! | journal = Ann. Rheum. Dis. | volume = 65 | issue = 11 | pages = 1403–5 | year = 2006 | month = November | pmid = 17038451 | pmc = 1798356 | doi = 10.1136/ard.2006.061994 }}</ref> |
The development of OA is correlated with a history of previous joint injury and with obesity, especially with respect to knees.<ref name="pmid11360143">{{cite journal | author = Coggon D, Reading I, Croft P, McLaren M, Barrett D, Cooper C | title = Knee osteoarthritis and obesity | journal = Int. J. Obes. Relat. Metab. Disord. | volume = 25 | issue = 5 | pages = 622–7 | year = 2001 | month = May | pmid = 11360143 | doi = 10.1038/sj.ijo.0801585 }}</ref> Since the correlation with obesity has been observed not only for knees but also for non-weight bearing joints and the loss of body fat is more closely related to symptom relief than the loss of body weight, it has been suggested that there may be a metabolic link to body fat as opposed to just mechanical loading.<ref name="pmid17038451">{{cite journal | author = Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F | title = Obesity and osteoarthritis: more complex than predicted! | journal = Ann. Rheum. Dis. | volume = 65 | issue = 11 | pages = 1403–5 | year = 2006 | month = November | pmid = 17038451 | pmc = 1798356 | doi = 10.1136/ard.2006.061994 }}</ref> |
Revision as of 23:14, 2 December 2013
Osteoarthritis | |
---|---|
Specialty | Family medicine, orthopedic surgery, rheumatology |
Osteoarthritis (OA) also known as degenerative arthritis or degenerative joint disease or osteoarthrosis, is a group of mechanical abnormalities involving degradation of joints,[1] including articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion. A variety of causes—hereditary, developmental, metabolic, and mechanical deficits—may initiate processes leading to loss of cartilage. When bone surfaces become less well protected by cartilage, bone may be exposed and damaged. As a result of decreased movement secondary to pain, regional muscles may atrophy, and ligaments may become more lax.[2]
Treatment generally involves a combination of exercise, lifestyle modification, and analgesics. If pain becomes debilitating, joint replacement surgery may be used to improve the quality of life. OA is the most common form of arthritis,[2] and the leading cause of chronic disability in the United States.[3] It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States.[4]
Signs and symptoms
The main symptom is pain, causing loss of ability and often stiffness. "Pain" is generally described as a sharp ache or a burning sensation in the associated muscles and tendons. OA can cause a crackling noise (called "crepitus") when the affected joint is moved or touched and people may experience muscle spasms and contractions in the tendons. Occasionally, the joints may also be filled with fluid.[5] Some people report increased pain associated with cold temperature, high humidity, and/or a drop in barometric pressure, but studies have had mixed results.[6]
OA commonly affects the hands, feet, spine, and the large weight bearing joints, such as the hips and knees, although in theory, any joint in the body can be affected. As OA progresses, the affected joints appear larger, are stiff and painful, and usually feel better with gentle use but worse with excessive or prolonged use, thus distinguishing it from rheumatoid arthritis.
In smaller joints, such as at the fingers, hard bony enlargements, called Heberden's nodes (on the distal interphalangeal joints) and/or Bouchard's nodes (on the proximal interphalangeal joints), may form, and though they are not necessarily painful, they do limit the movement of the fingers significantly. OA at the toes leads to the formation of bunions, rendering them red or swollen. Some people notice these physical changes before they experience any pain.
OA is the most common cause of a joint effusion of the knee.[7]
Causes
Damage from mechanical stress with insufficient self repair by joints is believed to be the primary cause of osteoarthritis.[8] Sources of this stress may include: misalignments of bones caused by congenital or pathogenic causes; mechanical injury; excess body weight; loss of strength in the muscles supporting a joint; and impairment of peripheral nerves, leading to sudden or uncoordinated movements.[8] However exercise, including running in the absence of injury, has not been found to increase the risk.[9] Nor has cracking one's knuckles been found to play a role.[10]
Primary
A number of studies have shown that there is a greater prevalence of the disease among siblings and especially identical twins, indicating a hereditary basis.[11] Although a single factor is not generally sufficient to cause the disease, about half of the variation in susceptibility has been assigned to genetic factors.[12]
As early human ancestors evolved into bipeds, changes occurred in the pelvis, hip joint and spine which increased the risk of osteoarthritis.[13] Additionally genetic variations that increase the risk were likely not selected against because usually problems only occur after reproductive success.[14]
The development of OA is correlated with a history of previous joint injury and with obesity, especially with respect to knees.[15] Since the correlation with obesity has been observed not only for knees but also for non-weight bearing joints and the loss of body fat is more closely related to symptom relief than the loss of body weight, it has been suggested that there may be a metabolic link to body fat as opposed to just mechanical loading.[16]
Changes in sex hormone levels may play a role in the development of OA as it is more prevalent among post-menopausal women than among men of the same age.[17][18] A study of mice found natural female hormones to be protective while injections of the male hormone dihydrotestosterone reduced protection.[19]
Secondary
This type of OA is caused by other factors but the resulting pathology is the same as for primary OA:
- Alkaptonuria
- Congenital disorders of joints
- Diabetes
- Ehlers-Danlos Syndrome
- Hemochromatosis and Wilson's disease
- Inflammatory diseases (such as Perthes' disease), (Lyme disease), and all chronic forms of arthritis (e.g. costochondritis, gout, and rheumatoid arthritis). In gout, uric acid crystals cause the cartilage to degenerate at a faster pace.
- Injury to joints or ligaments (such as the ACL), as a result of an accident or orthopedic operations.
- Ligamentous deterioration or instability may be a factor.
- Marfan syndrome
- Obesity
- Septic arthritis (infection of a joint)
Pathophysiology
Primary OA is a chronic degenerative disorder related to but not caused by aging, as there are people well into their nineties who have no clinical or functional signs of the disease. As a person ages, the water content of the cartilage decreases[20][better source needed] as a result of a reduced proteoglycan content, thus causing the cartilage to be less resilient. The water content of healthy cartilage is finely balanced by compressive force driving water out & swelling pressure drawing water in.[21] Collagen fibres exert the compressive force, whereas the Gibbs-Donnan effect & cartilage proteoglycans create osmotic pressure which tends to draw water in.[21] However during onset of OA there is an increase in cartilage water content.[22][23][24][25][26] This increase occurs because whilst there is an overall loss of proteoglycans,[23][27] it is outweighed by a loss of collagen.[21][27] Without the protective effects of the proteoglycans, the collagen fibers of the cartilage can become susceptible to degradation and thus exacerbate the degeneration. Inflammation of the surrounding joint capsule can also occur, though often mild (compared to what occurs in rheumatoid arthritis). This can happen as breakdown products from the cartilage are released into the synovial space, and the cells lining the joint attempt to remove them. New bone outgrowths, called "spurs" or osteophytes, can form on the margins of the joints, possibly in an attempt to improve the congruence of the articular cartilage surfaces. These bone changes, together with the inflammation, can be both painful and debilitating.
Diagnosis
Diagnosis is made with reasonable certainty based on history and clinical examination.[28][29] X-rays may confirm the diagnosis. The typical changes seen on X-ray include: joint space narrowing, subchondral sclerosis (increased bone formation around the joint), subchondral cyst formation, and osteophytes.[30] Plain films may not correlate with the findings on physical examination or with the degree of pain.[31] Usually other imaging techniques are not necessary to clinically diagnose OA.
In 1990, the American College of Rheumatology, using data from a multi-center study, developed a set of criteria for the diagnosis of hand OA based on hard tissue enlargement and swelling of certain joints.[32] These criteria were found to be 92% sensitive and 98% specific for hand OA versus other entities such as rheumatoid arthritis and spondyloarthropathies.[33]
Related pathologies whose names may be confused with OA include pseudo-arthrosis. This is derived from the Greek words pseudo, meaning "false", and arthrosis, meaning "joint." Radiographic diagnosis results in diagnosis of a fracture within a joint, which is not to be confused with OA which is a degenerative pathology affecting a high incidence of distal phalangeal joints of female patients. A polished ivory-like appearance may also develop on the bones of the affected joints, reflecting a change called eburnation.[34]
-
Damaged cartilage from sows. (a) cartilage erosion (b)cartilage ulceration (c)cartilage repair (d)osteophyte (bone spur) formation.
-
Histopathology of osteoarthrosis of a knee joint in an elderly female.
-
Histopathology of osteoarthrosis of a knee joint in an elderly female.
-
Severe osteoarthritis and osteopenia of the carpal joint and 1st carpometacarpel joint.
Classification
OA can be classified into either primary or secondary depending on whether or not there is an identifiable underlying cause.
Both primary generalized nodal OA and erosive OA (EOA, also called inflammatory OA) are sub-sets of primary OA. EOA is a much less common, and more aggressive inflammatory form of OA which often affects the distal interphalangeal joints of the hand and has characteristic articular erosive changes on x-ray.[35]
Management
Lifestyle modification (such as weight loss and exercise) and analgesics are the mainstay of treatment. Acetaminophen ( also known as paracetamol) is recommended first line with NSAIDs being used as add on therapy only if pain relief is not sufficient.[36] This is due to the relative greater safety of acetaminophen.[36]
Lifestyle modification
For overweight people, weight loss may be an important factor. Patient education has been shown to be helpful in the self-management of arthritis. It decreases pain, improves function, reduces stiffness and fatigue, and reduces medical usage.[37] Patient education can provide on average 20% more pain relief when compared to NSAIDs alone in patients with hip OA.[37]
Physical measures
Moderate exercise is beneficial with respect to pain and function in those with osteoathritis of the knee and possibly hip.[38] While some evidence supports certain physical therapies evidence for a combined program is limited.[39] There is not enough evidence to determine the effectiveness of massage therapy.[40]
The use of orthoses (which include splints, braces or insoles) have been studied. Lateral wedge insoles do not appear to be useful in osteoarthritis of the knee.[41][42] Knee braces may be useful.[43]
The evidence for manual therapy is inconclusive.[44] Functional, gait, and balance training has been recommended to address impairments of position sense, balance, and strength in individuals with lower extremity arthritis as these can contribute to higher falls in older individuals.[45]
Medication
The analgesic acetaminophen is the first line treatment for OA.[36][46] For mild to moderate symptoms effectiveness is similar to non-steroidal anti-inflammatory drugs (NSAIDs), though for more severe symptoms NSAIDs may be more effective.[36] NSAIDs such as naproxen while more effective in severe cases are associated with greater side effects such as gastrointestinal bleeding.[36] Another class of NSAIDs, COX-2 selective inhibitors (such as celecoxib) are equally effective to NSAIDs with lower rates of adverse gastrointestinal effects but higher rates of cardiovascular disease such as myocardial infarction.[47] They are also much more expensive. Oral steroids are not recommended in the treatment of OA because of their modest benefit and high rate of adverse effects.[citation needed]
There are several NSAIDs available for topical use including diclofenac. They have fewer systemic side-effects and at least some therapeutic effect.[48] A Cochrane review concluded that opioid analgesics such as morphine and fentanyl reduce pain, but this benefit is outweighed by frequent adverse events and thus they should not routinely be used.[49] Topical capsaicin is controversial with some reviews finding benefit[50][51] and others not.[48]
Injection of glucocorticoids (such as hydrocortisone) leads to short term pain relief that may last between a few weeks and a few months.[52] Joint injections of hyaluronic acid have not been found to lead to significant improvement.[48][53] Hyaluronic acid injects have been associated with significant harm.[53] Nevertheless another study about hyaluronic acid injections says efficacy on pain and function, and no adverse effect when compared to saline injections.[54]
Surgery
If disability is significant and more conservative management is ineffective, joint replacement surgery or resurfacing may be recommended. Evidence supports joint replacement for both knees and hips.[55] For the knee it improves both pain and functioning.[56] Arthroscopic surgical intervention for OA of the knee however has been found to be no better than placebo at relieving symptoms.[57]
Alternative medicine
Dietary supplements
Many dietary supplements are sold as treatments for OA and some of them have been found to be effective. Phytodolor,[50] SAMe,[58] and SKI 306X (a Chinese herbal mixture)[51] may be effective in improving pain, and there is some evidence to support the use of cat's claw as an anti-inflammatory.[59] There is tentative evidence to support avocado/soybean unsaponifiables,[51][60] Boswellia serrata extracts (frankincense),[61][62] MSM[50] and rose hip.[50]
The effectiveness of glucosamine is controversial.[63][64] Most recent reviews found it to be equal to[65][66] or only slight better than placebo.[67][68] A difference may exist between glucosamine sulfate and glucosamine hydrochloride, with glucosamine sulfate showing a benefit and glucosamine hydrochloride not.[69] The Osteoarthritis Research Society International recommends that glucosamine be discontinued if no effect is observed after six months[70] and the National Institute of Clinical Excellence no longer recommends its use.[2] Despite the difficulty in determining the efficacy of glucosamine, it remains a viable treatment option.[71]
There is little evidence supporting benefits for some supplements, including: the Ayurvedic herbal preparations with brand names Articulin F and Eazmov, collagen, devil’s claw, Duhuo Jisheng Wan (a Chinese herbal preparation), fish liver oil, ginger, the herbal preparation Gitadyl, glucosamine, hyaluronic acid, omega-3 fatty acids, the brand-name product Reumalax, stinging nettle, turmeric, vitamins A, C, and E in combination, vitamin E alone, vitamin K and willow bark. There is insufficient evidence to make a recommendation about the safety and efficacy of these treatments.[50][59] Chondroitin is not recommended as a treatment for OA.[72]
Manual therapies
While acupuncture leads to a statistically significant improvement in pain relief, this improvement is small and may be of questionable clinical significance. Waiting list-controlled trials for peripheral joint osteoarthritis do show clinically relevant benefits, but these may be due to placebo effects.[73] Acupuncture does not seem to produce long-term benefits.[74] While electrostimulation techniques such as TENS have been used for twenty years to treat osteoarthritis in the knee, there is no conclusive evidence to show that it reduces pain or disability.[75]
Epidemiology
Globally approximately 250 million people have osteoarthritis of the knee (3.6% of the population).[77] OA affects nearly 27 million people in the United States, accounting for 25% of visits to primary care physicians, and half of all NSAID prescriptions. It is estimated that 80% of the population have radiographic evidence of OA by age 65, although only 60% of those will have symptoms.[78] In the United States, hospitalizations for OA increased from 322,000 in 1993 to 735,000 in 2006.[79]
Globally OA causes moderate to severe disability in 43.4 million people as of 2004.[80]
In the United States, there were approximately 964,000 hospitalizations for osteoarthritis in 2011, a rate of 31 stays per 10,000 population.[81] With an aggregate cost of $14.8 billion, it was the second-most expensive condition seen in U.S. hospital stays in 2011. By payer, it was the second-most costly condition billed to Medicare and private insurance.[82]
Etymology
OA is derived from the Greek word part osteo-, meaning "of the bone", combined with arthritis: arthr-, meaning "joint", and -itis, the meaning of which has come to be associated with inflammation. The -itis of OA could be considered misleading as inflammation is not a conspicuous feature. Some clinicians refer to this condition as osteoarthosis to signify the lack of inflammatory response.
History
Evidence for OA found in the fossil record is studied by paleopathologists, specialists in ancient disease and injury. OA has been reported in fossils of the large carnivorous dinosaur Allosaurus fragilis.[83]
Research
There are ongoing efforts to determine if there are agents that modify outcomes in OA. Sprifermin is one candidate drug. There is also tentative evidence that strontium ranelate may decrease degeneration in OA and improve outcomes.[84][85]
References
- ^ "osteoarthritis" at Dorland's Medical Dictionary
- ^ a b c Conaghan P. "Osteoarthritis — National clinical guideline for care and management in adults" (PDF). Retrieved 2008-04-29.
- ^ Centers for Disease Control and Prevention (CDC) (2001). "Prevalence of disabilities and associated health conditions among adults--United States, 1999". MMWR Morb. Mortal. Wkly. Rep. 50 (7): 120–5. PMID 11393491.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Van Manen MD, Nace J, Mont MA (2012). "Management of primary knee osteoarthritis and indications for total knee arthroplasty for general practitioners". J Am Osteopath Assoc. 112 (11): 709–15. PMID 23139341.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ MedlinePlus Encyclopedia: Osteoarthritis
- ^ de Figueiredo EC, Figueiredo GC, Dantas RT (2011). "Influência de elementos meteorológicos na dor de pacientes com osteoartrite: Revisão da literatura". Rev Bras Reumatol (in Portuguese). 51 (6): 622–8. doi:10.1590/S0482-50042011000600008. PMID 22124595.
{{cite journal}}
: Unknown parameter|month=
ignored (help); Unknown parameter|trans_title=
ignored (|trans-title=
suggested) (help)CS1 maint: multiple names: authors list (link) - ^ "Water on the knee". MayoClinic.com.
- ^ a b Brandt KD, Dieppe P, Radin E (2009). "Etiopathogenesis of osteoarthritis". Med. Clin. North Am. 93 (1): 1–24, xv. doi:10.1016/j.mcna.2008.08.009. PMID 19059018.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Bosomworth NJ (2009). "Exercise and knee osteoarthritis: benefit or hazard?". Can Fam Physician. 55 (9): 871–8. PMC 2743580. PMID 19752252.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Deweber K, Olszewski M, Ortolano R (2011). "Knuckle cracking and hand osteoarthritis". J Am Board Fam Med. 24 (2): 169–74. doi:10.3122/jabfm.2011.02.100156. PMID 21383216.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Valdes AM, Spector TD (2008). "The contribution of genes to osteoarthritis". Rheum. Dis. Clin. North Am. 34 (3): 581–603. doi:10.1016/j.rdc.2008.04.008. PMID 18687274.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Spector TD, MacGregor AJ (2004). "Risk factors for osteoarthritis: genetics". Osteoarthr. Cartil. 12 Suppl A: S39–44. doi:10.1016/j.joca.2003.09.005. PMID 14698640.
- ^ Hogervorst, T (2009 Aug). "Evolution of the hip and pelvis". Acta orthopaedica. Supplementum. 80 (336): 1–39. PMID 19919389.
{{cite journal}}
: Check date values in:|date=
(help); Unknown parameter|coauthors=
ignored (|author=
suggested) (help) - ^ van der Kraan, PM (2008 Apr). "Osteoarthritis in the context of ageing and evolution. Loss of chondrocyte differentiation block during ageing". Ageing research reviews. 7 (2): 106–13. PMID 18054526.
{{cite journal}}
: Check date values in:|date=
(help); Unknown parameter|coauthors=
ignored (|author=
suggested) (help) - ^ Coggon D, Reading I, Croft P, McLaren M, Barrett D, Cooper C (2001). "Knee osteoarthritis and obesity". Int. J. Obes. Relat. Metab. Disord. 25 (5): 622–7. doi:10.1038/sj.ijo.0801585. PMID 11360143.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Pottie P, Presle N, Terlain B, Netter P, Mainard D, Berenbaum F (2006). "Obesity and osteoarthritis: more complex than predicted!". Ann. Rheum. Dis. 65 (11): 1403–5. doi:10.1136/ard.2006.061994. PMC 1798356. PMID 17038451.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Linn S, Murtaugh B, Casey E (2012). "Role of sex hormones in the development of osteoarthritis". PM R. 4 (5 Suppl): S169–73. doi:10.1016/j.pmrj.2012.01.013. PMID 22632696.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Tanamas SK, Wijethilake P, Wluka AE, Davies-Tuck ML, Urquhart DM, Wang Y, Cicuttini FM (2011). "Sex hormones and structural changes in osteoarthritis: a systematic review". Maturitas. 69 (2): 141–56. doi:10.1016/j.maturitas.2011.03.019. PMID 21481553.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS (2007). "Osteoarthritis severity is sex dependent in a surgical mouse model". Osteoarthr. Cartil. 15 (6): 695–700. doi:10.1016/j.joca.2006.11.005. PMID 17207643.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Simon, H (2005-05-08). "Osteoarthritis". University of Maryland Medical Center. Retrieved 2009-04-25.
{{cite web}}
: Unknown parameter|coauthors=
ignored (|author=
suggested) (help) - ^ a b c Maroudas AI (1976). "Balance between swelling pressure and collagen tension in normal and degenerate cartilage". Nature. 260 (5554): 808–9. doi:10.1038/260808a0. PMID 1264261.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Bollet AJ, Nance JL (1966). "Biochemical Findings in Normal and Osteoarthritic Articular Cartilage. II. Chondroitin Sulfate Concentration and Chain Length, Water, and Ash Content". J. Clin. Invest. 45 (7): 1170–7. doi:10.1172/JCI105423. PMC 292789. PMID 16695915.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ a b Brocklehurst R, Bayliss MT, Maroudas A, Coysh HL, Freeman MA, Revell PA, Ali SY (1984). "The composition of normal and osteoarthritic articular cartilage from human knee joints. With special reference to unicompartmental replacement and osteotomy of the knee". J Bone Joint Surg Am. 66 (1): 95–106. PMID 6690447.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Chou MC, Tsai PH, Huang GS, Lee HS, Lee CH, Lin MH, Lin CY, Chung HW (2009). "Correlation between the MR T2 value at 4.7 T and relative water content in articular cartilage in experimental osteoarthritis induced by ACL transection". Osteoarthr. Cartil. 17 (4): 441–7. doi:10.1016/j.joca.2008.09.009. PMID 18990590.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Grushko G, Schneiderman R, Maroudas A (1989). "Some biochemical and biophysical parameters for the study of the pathogenesis of osteoarthritis: a comparison between the processes of ageing and degeneration in human hip cartilage". Connect. Tissue Res. 19 (2–4): 149–76. doi:10.3109/03008208909043895. PMID 2805680.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Mankin HJ, Thrasher AZ (1975). "Water content and binding in normal and osteoarthritic human cartilage". J Bone Joint Surg Am. 57 (1): 76–80. PMID 1123375.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ a b Venn M, Maroudas A (1977). "Chemical composition and swelling of normal and osteoarthrotic femoral head cartilage. I. Chemical composition". Ann. Rheum. Dis. 36 (2): 121–9. doi:10.1136/ard.36.2.121. PMC 1006646. PMID 856064.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, Herrero-Beaumont G, Kirschner S, Leeb BF, Lohmander LS, Mazières B, Pavelka K, Punzi L, So AK, Tuncer T, Watt I, Bijlsma JW (2010). "EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis". Ann. Rheum. Dis. 69 (3): 483–9. doi:10.1136/ard.2009.113100. PMID 19762361.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Bierma-Zeinstra SM, Oster JD, Bernsen RM, Verhaar JA, Ginai AZ, Bohnen AM (2002). "Joint space narrowing and relationship with symptoms and signs in adults consulting for hip pain in primary care". J. Rheumatol. 29 (8): 1713–8. PMID 12180735.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Osteoarthritis (OA): Joint Disorders at Merck Manual of Diagnosis and Therapy Professional Edition
- ^ Phillips CR, Brasington RD (2010). "Osteoarthritis treatment update: Are NSAIDs still in the picture?". Journal of Musculoskeletal Medicine. 27 (2).
- ^ Kalunian KC (2013). "Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)". UpToDate. Retrieved 15 February 2013.
- ^ Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke TD, Daniel W, Gray R (1990). "The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand". Arthritis Rheum. 33 (11): 1601–10. doi:10.1002/art.1780331101. PMID 2242058.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Vasan N, Tao L, Vikas B (2010). First Aid for the USMLE Step 1, 2010 (First Aid USMLE). McGraw-Hill Medical. p. 378. ISBN 0-07-163340-5.
{{cite book}}
: CS1 maint: multiple names: authors list (link) - ^ Punzi L, Ramonda R, Sfriso P (2004). "Erosive osteoarthritis". Best Pract Res Clin Rheumatol. 18 (5): 739–58. doi:10.1016/j.berh.2004.05.010. PMID 15454130.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ a b c d e Flood J (2010). "The role of acetaminophen in the treatment of osteoarthritis". Am J Manag Care. 16 (Suppl Management): S48–54. PMID 20297877.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ a b Cibulka MT, White DM, Woehrle J; et al. (2009). "Hip pain and mobility deficits—hip osteoarthritis: clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association". J Orthop Sports Phys Ther. 39 (4): A1–25. doi:10.2519/jospt.2009.0301. PMID 19352008.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Hagen KB, Dagfinrud H, Moe RH, Østerås N, Kjeken I, Grotle M, Smedslund G (2012). "Exercise therapy for bone and muscle health: an overview of systematic reviews". BMC Med. 10: 167. doi:10.1186/1741-7015-10-167. PMC 3568719. PMID 23253613.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) - ^ Wang SY, Olson-Kellogg B, Shamliyan TA, Choi JY, Ramakrishnan R, Kane RL (2012). "Physical therapy interventions for knee pain secondary to osteoarthritis: a systematic review". Annals of Internal Medicine. 157 (9): 632–44. doi:10.7326/0003-4819-157-9-201211060-00007. PMID 23128863.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ De Luigi AJ (2012). "Complementary and alternative medicine in osteoarthritis". PM R. 4 (5 Suppl): S122–33. doi:10.1016/j.pmrj.2012.01.012. PMID 22632691.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Penny P, Geere J, Smith TO (2013). "A systematic review investigating the efficacy of laterally wedged insoles for medial knee osteoarthritis". Rheumatol. Int. 33 (10): 2529–38. doi:10.1007/s00296-013-2760-x. PMID 23612781.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Parkes MJ, Maricar N, Lunt M, LaValley MP, Jones RK, Segal NA, Takahashi-Narita K, Felson DT (2013). "Lateral wedge insoles as a conservative treatment for pain in patients with medial knee osteoarthritis: a meta-analysis". JAMA. 310 (7): 722–30. doi:10.1001/jama.2013.243229. PMID 23989797.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Page CJ, Hinman RS, Bennell KL (2011). "Physiotherapy management of knee osteoarthritis". Int J Rheum Dis. 14 (2): 145–152. doi:10.1111/j.1756-185X.2011.01612.x. PMID 21518313.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ French HP, Brennan A, White B, Cusack T (2011). "Manual therapy for osteoarthritis of the hip or knee — a systematic review". Man Ther. 16 (2): 109–117. doi:10.1016/j.math.2010.10.011. PMID 21146444.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Sturnieks DL, Tiedemann A, Chapman K, Munro B, Murray SM, Lord SR (2004). "Physiological risk factors for falls in older people with lower limb arthritis". J. Rheumatol. 31 (11): 2272–9. PMID 15517643.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2007). "OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence". Osteoarthr. Cartil. 15 (9): 981–1000. doi:10.1016/j.joca.2007.06.014. PMID 17719803.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS (2008). "Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation". Health Technol Assess. 12 (11): 1–278, iii. PMID 18405470.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ a b c Altman R, Barkin RL (2009). "Topical therapy for osteoarthritis: clinical and pharmacologic perspectives". Postgrad Med. 121 (2): 139–47. doi:10.3810/pgm.2009.03.1986. PMID 19332972.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Nüesch E, Rutjes AW, Husni E, Welch V, Jüni P (2009). Nüesch, Eveline (ed.). "Oral or transdermal opioids for osteoarthritis of the knee or hip". Cochrane Database of Systematic Reviews (4): CD003115. doi:10.1002/14651858.CD003115.pub3. PMID 19821302.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ a b c d e De Silva V, El-Metwally A, Ernst E, Lewith G, Macfarlane GJ (2011). "Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review". Rheumatology (Oxford). 50 (5): 911–20. doi:10.1093/rheumatology/keq379. PMID 21169345.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ a b c Cameron M, Gagnier JJ, Little CV, Parsons TJ, Blümle A, Chrubasik S (2009). "Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part I: Osteoarthritis". Phytother Res. 23 (11): 1497–515. doi:10.1002/ptr.3007. PMID 19856319.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Arroll B, Goodyear-Smith F (2004). "Corticosteroid injections for osteoarthritis of the knee: meta-analysis". BMJ. 328 (7444): 869. doi:10.1136/bmj.38039.573970.7C. PMC 387479. PMID 15039276.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ a b Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S (2012). "Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis". Annals of Internal Medicine. 157 (3): 180–91. doi:10.7326/0003-4819-157-3-201208070-00473. PMID 22868835.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Miller LE, Block JE (2013). "US-Approved Intra-Articular Hyaluronic Acid Injections are Safe and Effective in Patients with Knee Osteoarthritis: Systematic Review and Meta-Analysis of Randomized, Saline-Controlled Trials". Clin Med Insights Arthritis Musculoskelet Disord. 6: 57–63. doi:10.4137/CMAMD.S12743. PMC 3767581. PMID 24027421.
- ^ Santaguida PL, Hawker GA, Hudak PL, Glazier R, Mahomed NN, Kreder HJ, Coyte PC, Wright JG (2008). "Patient characteristics affecting the prognosis of total hip and knee joint arthroplasty: a systematic review". Can J Surg. 51 (6): 428–36. PMC 2592576. PMID 19057730.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Carr AJ, Robertsson O, Graves S, Price AJ, Arden NK, Judge A, Beard DJ (2012). "Knee replacement". Lancet. 379 (9823): 1331–40. doi:10.1016/S0140-6736(11)60752-6. PMID 22398175.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Moseley JB, O'Malley K, Petersen NJ, Menke TJ, Brody BA, Kuykendall DH, Hollingsworth JC, Ashton CM, Wray NP (2002). "A controlled trial of arthroscopic surgery for osteoarthritis of the knee". N. Engl. J. Med. 347 (2): 81–8. doi:10.1056/NEJMoa013259. PMID 12110735.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Lopez, HL (2012 May). "Nutritional interventions to prevent and treat osteoarthritis. Part II: focus on micronutrients and supportive nutraceuticals". PM & R : the journal of injury, function, and rehabilitation. 4 (5 Suppl): S155–68. doi:10.1016/j.pmrj.2012.02.023. PMID 22632695.
{{cite journal}}
: Check date values in:|date=
(help) - ^ a b Rosenbaum CC, O'Mathúna DP, Chavez M, Shields K (2010). "Antioxidants and antiinflammatory dietary supplements for osteoarthritis and rheumatoid arthritis". Altern Ther Health Med. 16 (2): 32–40. PMID 20232616.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Pirotta M (2010). "Arthritis disease - the use of complementary therapies". Aust Fam Physician. 39 (9): 638–40. PMID 20877766.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Ernst E (2008). "Frankincense: systematic review". BMJ. 337: a2813. doi:10.1136/bmj.a2813. PMC 2605614. PMID 19091760.
- ^ Abdel-Tawab M, Werz O, Schubert-Zsilavecz M (2011). "Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data". Clin Pharmacokinet. 50 (6): 349–69. doi:10.2165/11586800-000000000-00000. PMID 21553931.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ The effects of Glucosamine Sulphate on OA of the knee joint. BestBets.
- ^ Burdett N, McNeil JD (2012). "Difficulties with assessing the benefit of glucosamine sulphate as a treatment for osteoarthritis". Int J Evid Based Healthc. 10 (3): 222–6. doi:10.1111/j.1744-1609.2012.00279.x. PMID 22925619.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S (2010). "Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis". BMJ. 341: c4675. doi:10.1136/bmj.c4675. PMC 2941572. PMID 20847017.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Wu D, Huang Y, Gu Y, Fan W (2013). "Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials". Int. J. Clin. Pract. 67 (6): 585–94. doi:10.1111/ijcp.12115. PMID 23679910.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Chou R, McDonagh MS, Nakamoto E, Griffin J (2011). Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review. Comparative Effectiveness Reviews. Rockville: Agency for Healthcare Research and Quality. PMID 22091473.
{{cite book}}
: CS1 maint: multiple names: authors list (link)[page needed] - ^ Miller KL, Clegg DO (2011). "Glucosamine and chondroitin sulfate". Rheum. Dis. Clin. North Am. 37 (1): 103–18. doi:10.1016/j.rdc.2010.11.007. PMID 21220090.
The best current evidence suggests that the effect of these supplements, alone or in combination, on OA pain, function, and radiographic change is marginal at best.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Rovati LC, Girolami F, Persiani S (2012). "Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties". Ther Adv Musculoskelet Dis. 4 (3): 167–80. doi:10.1177/1759720X12437753. PMC 3400104. PMID 22850875.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008). "OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines". Osteoarthr. Cartil. 16 (2): 137–62. doi:10.1016/j.joca.2007.12.013. PMID 18279766.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Henrotin Y, Mobasheri A, Marty M (2012). "Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?". Arthritis Res. Ther. 14 (1): 201. doi:10.1186/ar3657. PMC 3392795. PMID 22293240.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) - ^ Reichenbach S, Sterchi R, Scherer M, Trelle S, Bürgi E, Bürgi U, Dieppe PA, Jüni P (2007). "Meta-analysis: chondroitin for osteoarthritis of the knee or hip". Annals of Internal Medicine. 146 (8): 580–90. doi:10.7326/0003-4819-146-8-200704170-00009. PMID 17438317.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Manheimer E, Cheng K, Linde K, Lao L, Yoo J, Wieland S, van der Windt DA, Berman BM, Bouter LM (2010). Manheimer, Eric (ed.). "Acupuncture for peripheral joint osteoarthritis". Cochrane Database of Systematic Reviews (1): CD001977. doi:10.1002/14651858.CD001977.pub2. PMC 3169099. PMID 20091527.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Wang SM, Kain ZN, White PF (2008). "Acupuncture analgesia: II. Clinical considerations" (PDF). Anesth. Analg. 106 (2): 611–21, table of contents. doi:10.1213/ane.0b013e318160644d. PMID 18227323.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Rutjes AW, Nüesch E, Sterchi R, Kalichman L, Hendriks E, Osiri M, Brosseau L, Reichenbach S, Jüni P (2009). Rutjes, Anne WS (ed.). "Transcutaneous electrostimulation for osteoarthritis of the knee". Cochrane Database of Systematic Reviews (4): CD002823. doi:10.1002/14651858.CD002823.pub2. PMID 19821296.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov. 11, 2009.
{{cite web}}
: Check date values in:|accessdate=
(help) - ^ Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V; et al. (2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.
{{cite journal}}
: Explicit use of et al. in:|author=
(help); Unknown parameter|displayauthors=
ignored (|display-authors=
suggested) (help); Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Green GA (2001). "Understanding NSAIDs: from aspirin to COX-2". Clin Cornerstone. 3 (5): 50–60. doi:10.1016/S1098-3597(01)90069-9. PMID 11464731.
- ^ "Hospitalizations for Osteoarthritis Rising Sharply". Newswise.com. Retrieved September 4, 2008.
- ^ "Table 9: Estimated prevalence of moderate and severe disability (millions) for leading disabling conditions by age, for high-income and low- and middle-income countries, 2004". The Global Burden of Disease: 2004 Update. Geneva: World Health Organization. 2008. p. 35. ISBN 978-92-4-156371-0.
{{cite book}}
: External link in
(help); Unknown parameter|chapterurl=
|chapterurl=
ignored (|chapter-url=
suggested) (help) - ^ Pfuntner A., Wier L.M., Stocks C. Most Frequent Conditions in U.S. Hospitals, 2011. HCUP Statistical Brief #162. September 2013. Agency for Healthcare Research and Quality, Rockville, MD. [1]
- ^ Torio CM, Andrews RM (August 2013). "National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011". HCUP Statistical Brief #160. Rockville, MD: Agency for Healthcare Research and Quality.
- ^ Molnar, R. E. (2001). "Therapod Paleopathology: A Literature Survey". In Tanke, Darren H.; Carpenter, Kenneth; Skrepnick, Michael William (eds.). Mesozoic Vertebrate Life. Indiana University Press. pp. 337–63. ISBN 978-0-253-33907-2.
{{cite book}}
: External link in
(help); Unknown parameter|chapterurl=
|chapterurl=
ignored (|chapter-url=
suggested) (help) - ^ Civjan N (2012). Chemical Biology: Approaches to Drug Discovery and Development to Targeting Disease. John Wiley & Sons. p. 313. ISBN 9781118437674.
- ^ Bruyère O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY (2008). "Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system". BMC Musculoskelet Disord. 9: 165. doi:10.1186/1471-2474-9-165. PMC 2627841. PMID 19087296.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
External links
- American College of Rheumatology Factsheet on OA
- Osteoarthritis The Arthritis Foundation
- Treatment Guidelines. Osteoarthritis Research Society International. Recommendations for the management of hip and knee osteoarthritis. Part II OARSI Recommendations for Management of Hip & Knee OA 2007. Part III Changes in Evidence 2010.